Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
D. John Betteridge, Valentine Charlton-Menys, Helen M. Colhoun, Paul N. Durrington, John H. Fuller, Graham A. Hitman, Shona J. Livingstone, Michael I. Mackness, Andrew W. Neil, Margaret J. Thomason, The Lancet, 8-26-04

Patients with type 2 diabetes have a significantly increased risk for cardiovascular disease, but it has been a matter of speculation whether statin treatment would reduce heart attacks or stroke in diabetes patients without high LDL cholesterol. This study's findings in that regard were so significant that it was cut short 2 years ahead of schedule. The results: treatment with statins reduced "acute coronary heart disease by 36%, coronary revascularisations by 31%, and rate of stroke by 48%." Overall, "atorvastatin reduced the death rate by 27%" with "no excess of adverse events."

Recently, guidelines released by U.S. government officials and the American Heart Association recommended that patients at high risk of heart disease consider using statins to lower their cholesterol levels below previous guidelines. These recommendations were attacked by industry critics, who claimed the researchers' findings were tainted by their ties to industry. This study, which seems to support the U.S. findings, was primarily financed by British patient groups and the British government.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000